JP2024521879A - 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体 - Google Patents

置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体 Download PDF

Info

Publication number
JP2024521879A
JP2024521879A JP2023574163A JP2023574163A JP2024521879A JP 2024521879 A JP2024521879 A JP 2024521879A JP 2023574163 A JP2023574163 A JP 2023574163A JP 2023574163 A JP2023574163 A JP 2023574163A JP 2024521879 A JP2024521879 A JP 2024521879A
Authority
JP
Japan
Prior art keywords
alkyl
het
atom
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521879A5 (https=
Inventor
カイ，ウェイ
ウィルヘルムス ジェイ． チュリン，ヨハネス
ヒュルピア，ファビアン
ダイ，シュエドン
リ，ミン
デン，シャンジュン
リアン，チャオ
ティー ファイ エヌジー，アリシア
スン，ゼン
ジャン，チガオ
ドミニク デミン，サミュエル
ニコラエヴナ デュバンコバ，ナタリア
ジュフロワ，マチュー，ドミニク
レプリ，スーザン
フレディー ジェイクス ブルーノ ダーヴィレ，ニコラス
パンデ，ヴィニート
ベルト グリート シェペンス，ウィム
パトリック エドワーズ，ジェームス
アレクシス ジョルジュ ケロル，オリヴィエ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024521879A publication Critical patent/JP2024521879A/ja
Publication of JP2024521879A5 publication Critical patent/JP2024521879A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023574163A 2021-06-01 2022-05-30 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体 Pending JP2024521879A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021097679 2021-06-01
CNPCT/CN2021/097679 2021-06-01
CNPCT/CN2022/085680 2022-04-08
CN2022085680 2022-04-08
PCT/CN2022/095901 WO2022253167A1 (en) 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES

Publications (2)

Publication Number Publication Date
JP2024521879A true JP2024521879A (ja) 2024-06-04
JP2024521879A5 JP2024521879A5 (https=) 2025-05-30

Family

ID=82016507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574163A Pending JP2024521879A (ja) 2021-06-01 2022-05-30 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体

Country Status (19)

Country Link
US (1) US20230250096A1 (https=)
EP (1) EP4347588A1 (https=)
JP (1) JP2024521879A (https=)
KR (1) KR20240016324A (https=)
CN (1) CN117396476A (https=)
AR (1) AR126011A1 (https=)
AU (1) AU2022286467A1 (https=)
CA (1) CA3218479A1 (https=)
CL (1) CL2023003531A1 (https=)
CO (1) CO2023016217A2 (https=)
CR (1) CR20230605A (https=)
DO (1) DOP2023000250A (https=)
EC (1) ECSP23095641A (https=)
IL (1) IL308862A (https=)
MX (1) MX2023014347A (https=)
PE (1) PE20242359A1 (https=)
TW (1) TW202313606A (https=)
UY (1) UY39795A (https=)
WO (1) WO2022253167A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
US20250197392A1 (en) 2022-04-08 2025-06-19 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
WO2025119184A1 (zh) * 2023-12-04 2025-06-12 首药控股(北京)股份有限公司 取代的多环化合物
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529421A (ja) * 2016-09-16 2019-10-17 ヴァイティー ファーマシューティカルズ，エルエルシー ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
IN2014DN01883A (https=) 2011-09-14 2015-05-15 Proximagen Ltd
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
JP7618567B2 (ja) 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529421A (ja) * 2016-09-16 2019-10-17 ヴァイティー ファーマシューティカルズ，エルエルシー ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤

Also Published As

Publication number Publication date
DOP2023000250A (es) 2024-04-30
ECSP23095641A (es) 2024-01-31
AR126011A1 (es) 2023-08-30
PE20242359A1 (es) 2024-12-16
IL308862A (en) 2024-01-01
CO2023016217A2 (es) 2023-12-11
CN117396476A (zh) 2024-01-12
EP4347588A1 (en) 2024-04-10
TW202313606A (zh) 2023-04-01
CA3218479A1 (en) 2022-12-08
WO2022253167A1 (en) 2022-12-08
UY39795A (es) 2022-11-30
CL2023003531A1 (es) 2024-06-14
MX2023014347A (es) 2023-12-13
AU2022286467A1 (en) 2024-01-25
US20230250096A1 (en) 2023-08-10
WO2022253167A8 (en) 2023-03-09
CR20230605A (es) 2024-05-24
KR20240016324A (ko) 2024-02-06

Similar Documents

Publication Publication Date Title
JP2024521879A (ja) 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
KR101946911B1 (ko) 신규한 인돌리진 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
AU2019264640A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
EP3129374A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
JP2024518425A (ja) 置換スピロ誘導体
JP2024518434A (ja) 置換スピロ誘導体
JP2025513798A (ja) メニン／ｍｌｌ相互作用の阻害剤の結晶質形態
KR102513564B1 (ko) 메닌-mll 상호작용의 아제판 억제제
WO2024114666A1 (en) Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
JP2025541695A (ja) 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
JP2025540759A (ja) メニン－ｍｌｌ阻害剤及び少なくとも１つの他の治療剤を含む組み合わせ
JP2024521902A (ja) スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
ES2771151T3 (es) Derivados de piperidina como inhibidor de señalización wnt
JP2020512352A (ja) ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
CA3200758A1 (en) Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217